See more : PJP Makrum S.A. (PJP.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Lee’s Pharmaceutical Holdings Limited (LPCUF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lee’s Pharmaceutical Holdings Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aisin Corporation (ASEKY) Income Statement Analysis – Financial Results
- Mitsuboshi Co., Ltd. (5820.T) Income Statement Analysis – Financial Results
- Chuo Gyorui Co., Ltd. (8030.T) Income Statement Analysis – Financial Results
- DTE Energy Company 2020 Series (DTB) Income Statement Analysis – Financial Results
- Peak Resources LP (PRB) Income Statement Analysis – Financial Results
Lee's Pharmaceutical Holdings Limited (LPCUF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.leespharm.com
About Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.23B | 1.27B | 1.22B | 1.22B | 1.14B | 1.01B | 929.82M | 922.15M | 955.21M | 696.95M | 534.33M | 399.69M | 255.81M | 173.84M | 125.42M | 76.71M | 43.53M | 38.53M | 30.40M | 18.50M | 11.64M | 10.35M |
| Cost of Revenue | 501.72M | 462.39M | 459.87M | 435.65M | 420.66M | 391.26M | 326.12M | 261.59M | 273.99M | 284.69M | 193.70M | 153.50M | 107.85M | 77.32M | 49.26M | 36.78M | 25.72M | 16.86M | 13.22M | 10.38M | 5.13M | 3.20M | 2.47M |
| Gross Profit | 551.31M | 770.76M | 806.28M | 781.07M | 798.26M | 746.37M | 682.40M | 668.24M | 648.16M | 670.52M | 503.25M | 380.84M | 291.83M | 178.49M | 124.58M | 88.64M | 50.99M | 26.67M | 25.31M | 20.01M | 13.36M | 8.44M | 7.88M |
| Gross Profit Ratio | 52.35% | 62.50% | 63.68% | 64.19% | 65.49% | 65.61% | 67.66% | 71.87% | 70.29% | 70.20% | 72.21% | 71.27% | 73.02% | 69.77% | 71.66% | 70.68% | 66.47% | 61.27% | 65.70% | 65.85% | 72.25% | 72.52% | 76.16% |
| Research & Development | 96.80M | 168.89M | 243.84M | 203.29M | 149.95M | 153.17M | 85.06M | 67.89M | 47.08M | 37.96M | 32.26M | 16.30M | 11.84M | 5.59M | 5.69M | 2.10M | 1.50M | 1.11M | 878.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 188.61M | 198.41M | 297.27M | 237.72M | 239.09M | 188.93M | 159.22M | 146.51M | 112.31M | 99.35M | 78.51M | 63.04M | 37.09M | 29.30M | 22.49M | 19.95M | 14.19M | 14.74M | 11.04M | 10.17M | 12.05M | 8.42M | 5.23M |
| Selling & Marketing | 304.30M | 346.47M | 366.44M | 279.95M | 251.76M | 221.74M | 214.15M | 204.23M | 256.47M | 309.20M | 222.85M | 179.51M | 156.44M | 79.19M | 47.84M | 36.98M | 22.60M | 14.42M | 14.61M | 13.21M | 6.85M | 5.03M | 5.38M |
| SG&A | 492.91M | 544.88M | 663.70M | 517.67M | 490.85M | 410.67M | 373.37M | 350.74M | 368.78M | 408.55M | 301.36M | 242.55M | 193.53M | 108.49M | 70.33M | 56.94M | 36.79M | 29.16M | 25.65M | 23.38M | 18.90M | 13.45M | 10.62M |
| Other Expenses | -81.95M | -19.28M | -18.16M | -29.78M | -29.49M | -14.17M | 2.98M | 1.74M | 713.00K | 3.58M | 4.46M | 4.49M | -5.49M | -5.37M | -4.83M | -1.25M | -746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 507.76M | 694.49M | 889.38M | 691.18M | 611.30M | 549.67M | 434.30M | 350.86M | 409.23M | 437.80M | 330.70M | 252.94M | 199.87M | 108.71M | 71.18M | 57.79M | 37.54M | 30.27M | 26.53M | 23.38M | 18.90M | 13.45M | 10.62M |
| Cost & Expenses | 1.01B | 1.16B | 1.35B | 1.13B | 1.03B | 940.92M | 760.42M | 612.45M | 683.22M | 722.48M | 524.40M | 406.44M | 307.72M | 186.03M | 120.44M | 94.57M | 63.26M | 47.13M | 39.74M | 33.76M | 24.04M | 16.65M | 13.08M |
| Interest Income | 1.53M | 2.39M | 5.91M | 9.07M | 11.02M | 9.83M | 7.47M | 2.64M | 4.87M | 3.50M | 3.35M | 1.98M | 390.00K | 164.00K | 79.00K | 236.00K | 227.00K | 131.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.90M | 6.62M | 4.40M | 5.39M | 5.76M | 4.16M | 3.86M | 3.40M | 2.61M | 2.45M | 1.56M | 1.03M | 648.00K | 904.00K | 601.00K | 428.00K | 755.00K | 704.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 149.50M | 152.50M | 146.87M | 127.50M | 94.14M | 65.08M | 58.11M | 45.73M | 44.50M | 28.89M | 16.50M | 14.52M | 10.99M | 7.55M | 5.16M | 3.35M | 2.73M | 2.38M | 2.05M | 2.03M | 2.05M | 1.95M | 1.46M |
| EBITDA | 191.56M | 229.06M | 2.13B | 279.43M | 235.55M | 516.17M | 319.99M | 332.14M | 301.05M | 259.71M | 194.45M | 148.72M | 109.73M | 76.42M | 58.57M | 34.44M | 16.40M | -294.00K | 836.00K | -1.34M | -3.49M | -3.05M | -1.28M |
| EBITDA Ratio | 18.19% | 22.34% | 11.54% | 23.11% | 27.79% | 45.59% | 31.41% | 38.55% | 28.10% | 28.04% | 27.86% | 27.83% | 25.76% | 29.78% | 33.68% | 27.39% | 21.21% | -2.79% | 2.17% | -4.39% | -18.88% | -26.19% | -12.33% |
| Operating Income | 43.55M | 123.02M | -694.00K | 151.92M | 244.60M | 466.94M | 276.83M | 298.43M | 286.43M | 231.49M | 180.36M | 134.36M | 98.79M | 70.18M | 53.47M | 31.09M | 13.68M | -2.68M | 555.00K | -2.74M | -4.83M | -4.79M | -2.00M |
| Operating Income Ratio | 4.14% | 9.98% | -0.05% | 12.49% | 20.07% | 41.04% | 27.45% | 32.09% | 31.06% | 24.23% | 25.88% | 25.15% | 24.72% | 27.43% | 30.76% | 24.79% | 17.83% | -6.15% | 1.44% | -9.02% | -26.09% | -41.09% | -19.31% |
| Total Other Income/Expenses | -12.77M | -8.70M | -9.22M | -17.89M | -18.52M | 261.49M | 18.90M | -12.74M | 6.10M | -8.16M | -926.00K | 1.04M | -1.04M | -2.22M | -689.00K | -505.00K | -890.00K | -704.00K | 1.32M | 58.00K | -593.00K | -596.00K | 681.00K |
| Income Before Tax | 30.79M | 67.86M | 1.97B | 134.04M | 122.89M | 446.38M | 257.63M | 282.60M | 253.94M | 228.15M | 176.09M | 133.17M | 97.75M | 67.96M | 52.78M | 30.58M | 12.79M | -3.38M | 109.00K | -3.31M | -5.42M | -5.38M | -1.32M |
| Income Before Tax Ratio | 2.92% | 5.50% | 155.54% | 11.02% | 10.08% | 39.24% | 25.55% | 30.39% | 27.54% | 23.89% | 25.27% | 24.92% | 24.46% | 26.57% | 30.36% | 24.38% | 16.67% | -7.77% | 0.28% | -10.88% | -29.30% | -46.21% | -12.73% |
| Income Tax Expense | 10.84M | 22.03M | 9.48M | 55.50M | 59.54M | 56.62M | 54.69M | 50.20M | 40.94M | 41.37M | 27.09M | 20.10M | 13.73M | 10.04M | 6.41M | 2.52M | 1.42M | 88.00K | -44.00K | -40.00K | -56.00K | -1.53M | -1.42M |
| Net Income | 16.70M | 51.28M | 1.99B | 78.53M | 63.35M | 418.27M | 232.56M | 252.00M | 229.05M | 192.83M | 150.47M | 113.81M | 83.91M | 58.03M | 46.37M | 28.06M | 11.37M | -3.47M | 153.00K | -3.27M | -5.36M | -3.47M | -1.32M |
| Net Income Ratio | 1.59% | 4.16% | 156.95% | 6.45% | 5.20% | 36.77% | 23.06% | 27.10% | 24.84% | 20.19% | 21.59% | 21.30% | 20.99% | 22.68% | 26.67% | 22.37% | 14.82% | -7.97% | 0.40% | -10.75% | -28.99% | -29.77% | -12.73% |
| EPS | 0.03 | 0.09 | 3.38 | 0.13 | 0.11 | 0.71 | 0.39 | 0.43 | 0.40 | 0.36 | 0.28 | 0.23 | 0.18 | 0.13 | 0.11 | 0.07 | 0.03 | -0.01 | 0.00 | -0.01 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | 0.03 | 0.09 | 3.37 | 0.13 | 0.11 | 0.70 | 0.39 | 0.43 | 0.39 | 0.34 | 0.27 | 0.22 | 0.18 | 0.12 | 0.11 | 0.07 | 0.03 | -0.01 | 0.00 | -0.01 | -0.02 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 588.85M | 588.84M | 588.65M | 588.12M | 591.57M | 591.84M | 590.51M | 588.92M | 575.99M | 542.87M | 529.66M | 498.63M | 468.73M | 453.41M | 427.39M | 414.72M | 365.52M | 346.23M | 382.50M | 311.28M | 289.89M | 245.26M | 182.92M |
| Weighted Avg Shares Out (Dil) | 588.84M | 588.84M | 589.05M | 588.16M | 591.89M | 595.15M | 592.33M | 591.61M | 583.01M | 559.56M | 546.36M | 508.45M | 478.63M | 466.72M | 435.67M | 421.07M | 371.66M | 346.23M | 382.50M | 311.28M | 289.89M | 246.89M | 185.49M |
Source: https://incomestatements.info
Category: Stock Reports